AC Immune’s Parkinson’s vaccine advances on promising biomarker profile

A consistent, directionally favorable set of biomarker moves suggests AC Immune’s next-generation vaccine against Parkinson’s disease target α-synuclein is doing what it was designed to do.

On Thursday, AC Immune S.A. (NASDAQ:ACIU) told investors it is weighing whether to proceed with Part 2 of its Phase II VacSYn trial or advance directly into a registrational study, after Part 1 showed strong immunogenicity and a coherent biomarker profile in early Parkinson’s...